---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-090711"
form_type: "8-K"
ticker: "PTPI"
cik: "0001815903"
company_name: "Petros Pharmaceuticals, Inc."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-24T00:01:15.155582+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Petros Pharmaceuticals reports Q2 net sales of $4.2M, first positive adjusted EBITDA of $0.2M

## Summary
- Q2 net sales of $4.2M, up 68% from $2.5M in Q2 2021; net loss narrowed to $1.8M from $2.1M.
- First positive adjusted EBITDA of $0.2M, compared to negative $2.0M in prior-year period.
- Prescription Medicines segment (STENDRA) sales up 102% YoY to $3.3M; gross margin stable at 84%.
- Cash balance $13.3M as of June 30, 2022, down from $17.7M at March 31, 2022.
- Announced positive OTC label comprehension study for STENDRA and pursuit of 505(b)(2) pathway for H-100 for Peyronie's disease.

## SEC filing metadata
- accession: 0001104659-22-090711
- form_type: 8-K
- ticker: PTPI
- cik: 0001815903
- company_name: Petros Pharmaceuticals, Inc.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815903/000110465922090711/0001104659-22-090711-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815903/000110465922090711/tm2223325d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-090711
- JSON: https://secwatch.observer/filing/0001104659-22-090711.json
- Plain text: https://secwatch.observer/filing/0001104659-22-090711.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.